One major challenge in biomedical research is to leverage advances in genome sequencing into lead therapeutic modalities to treat human disease. This precision medicine approach holds great promise to advance patient-specific therapeutics and to provide highly selective chemical probes of function to study disease biology. In this proposal, we describe an innovative precision therapeutic approach to custom synthesize highly selective and potent lead therapeutics in only disease-affected cells and tissues by using a disease-causing gene product as a catalyst. That is, the disease-affected cell serves as a reaction vessel and a disease-causing RNA as a catalyst to allow for the synthesis of its own treatment. This is in contrast to traditional precision medicine approaches in which both healthy and disease-affected cells are exposed to the therapeutic, potentially causing toxicity due to binding off-targets. Our technology will be applied to develop compounds to treat and study microsatellite disorders that affect millions of people worldwide and have no known cure. Microsatellite disorders are caused by expanded repeating sequences located in both coding and non-coding regions, with the RNA being a key pathogenic agent. We have previously shown that repeating transcripts are most effectively targeted with multivalent compounds. However, as the compounds increase in valency, their molecular weights increase and their drug- likeness decreases. We therefore recently developed an innovative strategy to synthesize multivalent compounds, from their monovalent components, in cellulo using a disease-affected cell as a reaction vessel and a toxic, disease-causing RNA as a catalyst. We will take these exciting results in new directions and apply them to other debilitating microsatellite disorders including Huntington's disease, various forms of muscular dystrophy, the genetic defect that causes fragile X syndrome (the only known single gene cause of auti

Public Health Relevance

Herein, we propose to leverage genome-sequencing data to develop precise medicines to treat and study human neurological disease. In particular, we will custom synthesize highly selective and potent lead therapeutics in only disease-affected cells and tissues by using a disease-causing gene product as a catalyst, potentially allowing low molecular weight compounds to cross the blood-brain barrier and transform into potent, oligomeric inhibitors in disease-affected brain. Further, these compounds can be used to study disease pathology and image the disease-causing agent directly in cells and tissues of live animals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
5DP1NS096898-03
Application #
9308030
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Gubitz, Amelie
Project Start
2015-09-30
Project End
2020-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Scripps Florida
Department
Type
DUNS #
148230662
City
Jupiter
State
FL
Country
United States
Zip Code
33458
Guan, Lirui; Luo, Yiling; Ja, William W et al. (2018) Small molecule alteration of RNA sequence in cells and animals. Bioorg Med Chem Lett 28:2794-2796
Angelbello, Alicia J; Chen, Jonathan L; Childs-Disney, Jessica L et al. (2018) Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chem Rev 118:1599-1663
Wang, Zi-Fu; Ursu, Andrei; Childs-Disney, Jessica L et al. (2018) The Hairpin Form of r(G4C2)exp in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules. Cell Chem Biol :
Rzuczek, Suzanne G; Colgan, Lesley A; Nakai, Yoshio et al. (2017) Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nat Chem Biol 13:188-193
Gendron, Tania F; Chew, Jeannie; Stankowski, Jeannette N et al. (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med 9:
Chen, Jonathan L; VanEtten, Damian M; Fountain, Matthew A et al. (2017) Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1. Biochemistry 56:3463-3474
Disney, Matthew D; Angelbello, Alicia J (2016) Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence. Acc Chem Res 49:2698-2704
Yang, Wang-Yong; Gao, Rui; Southern, Mark et al. (2016) Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10. Nat Commun 7:11647
Angelbello, Alicia J; González, Àlex L; Rzuczek, Suzanne G et al. (2016) Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1. Bioorg Med Chem Lett 26:5792-5796
Yang, Wang-Yong; He, Fang; Strack, Rita L et al. (2016) Small Molecule Recognition and Tools to Study Modulation of r(CGG)(exp) in Fragile X-Associated Tremor Ataxia Syndrome. ACS Chem Biol 11:2456-65

Showing the most recent 10 out of 11 publications